Orphan Lilly antibiotic spurs $86.3 million IPO plan: Targanta Therapeutics aims to commercialize drug
A biotech company that’s attempting to commercialize an antibiotic developed by Eli Lilly and Co. has filed for an $86.3 million initial public offering. Targanta Therapeutics Corp. two years ago bought the rights to Lilly’s skin infection treatment, oritavancin. The company briefly had its headquarters in Indianapolis before moving it to Cambridge, Mass., last year. Lilly will see a big payoff if Targanta succeeds. The company’s IPO filing says it must pay the Indianapolis pharma giant $10 million when oritavancin…